Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
Identifieur interne :
003210 ( PascalFrancis/Corpus );
précédent :
003209;
suivant :
003211
Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
Auteurs : G. Meco ;
A. Alessandri ;
P. Giustini ;
V. BonifatiSource :
-
Movement disorders [ 0885-3185 ] ; 1997.
RBID : Pascal:97-0412076
Descripteurs français
English descriptors
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 12 |
---|
A06 | | | | @2 4 |
---|
A08 | 01 | 1 | ENG | @1 Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study |
---|
A11 | 01 | 1 | | @1 MECO (G.) |
---|
A11 | 02 | 1 | | @1 ALESSANDRI (A.) |
---|
A11 | 03 | 1 | | @1 GIUSTINI (P.) |
---|
A11 | 04 | 1 | | @1 BONIFATI (V.) |
---|
A14 | 01 | | | @1 Department of Neurological Sciences, "La Sapienza" University @2 Roma @3 ITA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. |
---|
A20 | | | | @1 610-612 |
---|
A21 | | | | @1 1997 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000067729910220 |
---|
A44 | | | | @0 0000 @1 © 1997 INIST-CNRS. All rights reserved. |
---|
A45 | | | | @0 9 ref. |
---|
A47 | 01 | 1 | | @0 97-0412076 |
---|
A60 | | | | @1 P |
---|
A61 | | | | @0 A |
---|
A64 | 01 | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C02 | 01 | X | | @0 002B02B03 |
---|
C03 | 01 | X | FRE | @0 Parkinson maladie @5 01 |
---|
C03 | 01 | X | ENG | @0 Parkinson disease @5 01 |
---|
C03 | 01 | X | SPA | @0 Parkinson enfermedad @5 01 |
---|
C03 | 02 | X | FRE | @0 Psychose @5 04 |
---|
C03 | 02 | X | ENG | @0 Psychosis @5 04 |
---|
C03 | 02 | X | SPA | @0 Psicosis @5 04 |
---|
C03 | 03 | X | FRE | @0 Rispéridone @2 NK @2 FR @5 07 |
---|
C03 | 03 | X | ENG | @0 Risperidone @2 NK @2 FR @5 07 |
---|
C03 | 03 | X | SPA | @0 Risperidona @2 NK @2 FR @5 07 |
---|
C03 | 04 | X | FRE | @0 Antipsychotique @5 08 |
---|
C03 | 04 | X | ENG | @0 Antipsychotic @5 08 |
---|
C03 | 04 | X | SPA | @0 Antipsicótico @5 08 |
---|
C03 | 05 | X | FRE | @0 Trouble cognition @5 10 |
---|
C03 | 05 | X | ENG | @0 Cognitive disorder @5 10 |
---|
C03 | 05 | X | SPA | @0 Trastorno cognitivo @5 10 |
---|
C03 | 06 | X | FRE | @0 Chimiothérapie @5 16 |
---|
C03 | 06 | X | ENG | @0 Chemotherapy @5 16 |
---|
C03 | 06 | X | SPA | @0 Quimioterapia @5 16 |
---|
C03 | 07 | X | FRE | @0 Traitement @5 17 |
---|
C03 | 07 | X | ENG | @0 Treatment @5 17 |
---|
C03 | 07 | X | GER | @0 Aufbereiten @5 17 |
---|
C03 | 07 | X | SPA | @0 Tratamiento @5 17 |
---|
C03 | 08 | X | FRE | @0 Homme @5 20 |
---|
C03 | 08 | X | ENG | @0 Human @5 20 |
---|
C03 | 08 | X | SPA | @0 Hombre @5 20 |
---|
C03 | 09 | X | FRE | @0 Etude longitudinale @5 23 |
---|
C03 | 09 | X | ENG | @0 Follow up study @5 23 |
---|
C03 | 09 | X | SPA | @0 Estudio longitudinal @5 23 |
---|
C03 | 10 | X | FRE | @0 Dose faible @5 24 |
---|
C03 | 10 | X | ENG | @0 Low dose @5 24 |
---|
C03 | 10 | X | SPA | @0 Dosis débil @5 24 |
---|
C07 | 01 | X | FRE | @0 Système nerveux pathologie @5 37 |
---|
C07 | 01 | X | ENG | @0 Nervous system diseases @5 37 |
---|
C07 | 01 | X | SPA | @0 Sistema nervioso patología @5 37 |
---|
C07 | 02 | X | FRE | @0 Système nerveux central pathologie @5 38 |
---|
C07 | 02 | X | ENG | @0 Central nervous system disease @5 38 |
---|
C07 | 02 | X | SPA | @0 Sistema nervosio central patología @5 38 |
---|
C07 | 03 | X | FRE | @0 Encéphale pathologie @5 39 |
---|
C07 | 03 | X | ENG | @0 Cerebral disorder @5 39 |
---|
C07 | 03 | X | SPA | @0 Encéfalo patología @5 39 |
---|
C07 | 04 | X | FRE | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | ENG | @0 Extrapyramidal syndrome @5 40 |
---|
C07 | 04 | X | SPA | @0 Extrapiramidal síndrome @5 40 |
---|
C07 | 05 | X | FRE | @0 Maladie dégénérative @5 41 |
---|
C07 | 05 | X | ENG | @0 Degenerative disease @5 41 |
---|
C07 | 05 | X | SPA | @0 Enfermedad degenerativa @5 41 |
---|
C07 | 06 | X | FRE | @0 Psychopathologie @5 45 |
---|
C07 | 06 | X | ENG | @0 Psychopathology @5 45 |
---|
C07 | 06 | X | SPA | @0 Psicopatología @5 45 |
---|
N21 | | | | @1 251 |
---|
|
Format Inist (serveur)
NO : | PASCAL 97-0412076 INIST |
ET : | Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study |
AU : | MECO (G.); ALESSANDRI (A.); GIUSTINI (P.); BONIFATI (V.) |
AF : | Department of Neurological Sciences, "La Sapienza" University/Roma/Italie (1 aut., 2 aut., 3 aut., 4 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 4; Pp. 610-612; Bibl. 9 ref. |
LA : | Anglais |
CC : | 002B02B03 |
FD : | Parkinson maladie; Psychose; Rispéridone; Antipsychotique; Trouble cognition; Chimiothérapie; Traitement; Homme; Etude longitudinale; Dose faible |
FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Psychopathologie |
ED : | Parkinson disease; Psychosis; Risperidone; Antipsychotic; Cognitive disorder; Chemotherapy; Treatment; Human; Follow up study; Low dose |
EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Psychopathology |
GD : | Aufbereiten |
SD : | Parkinson enfermedad; Psicosis; Risperidona; Antipsicótico; Trastorno cognitivo; Quimioterapia; Tratamiento; Hombre; Estudio longitudinal; Dosis débil |
LO : | INIST-20953.354000067729910220 |
ID : | 97-0412076 |
Links to Exploration step
Pascal:97-0412076
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</title>
<author><name sortKey="Meco, G" sort="Meco, G" uniqKey="Meco G" first="G." last="Meco">G. Meco</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alessandri, A" sort="Alessandri, A" uniqKey="Alessandri A" first="A." last="Alessandri">A. Alessandri</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Giustini, P" sort="Giustini, P" uniqKey="Giustini P" first="P." last="Giustini">P. Giustini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonifati, V" sort="Bonifati, V" uniqKey="Bonifati V" first="V." last="Bonifati">V. Bonifati</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">97-0412076</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 97-0412076 INIST</idno>
<idno type="RBID">Pascal:97-0412076</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003210</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</title>
<author><name sortKey="Meco, G" sort="Meco, G" uniqKey="Meco G" first="G." last="Meco">G. Meco</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alessandri, A" sort="Alessandri, A" uniqKey="Alessandri A" first="A." last="Alessandri">A. Alessandri</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Giustini, P" sort="Giustini, P" uniqKey="Giustini P" first="P." last="Giustini">P. Giustini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonifati, V" sort="Bonifati, V" uniqKey="Bonifati V" first="V." last="Bonifati">V. Bonifati</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Chemotherapy</term>
<term>Cognitive disorder</term>
<term>Follow up study</term>
<term>Human</term>
<term>Low dose</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Risperidone</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Psychose</term>
<term>Rispéridone</term>
<term>Antipsychotique</term>
<term>Trouble cognition</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude longitudinale</term>
<term>Dose faible</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA08 i1="01" i2="1" l="ENG"><s1>Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MECO (G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ALESSANDRI (A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GIUSTINI (P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BONIFATI (V.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>610-612</s1>
</fA20>
<fA21><s1>1997</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000067729910220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1997 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>9 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>97-0412076</s0>
</fA47>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Psychose</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Rispéridone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Risperidone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Risperidona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antipsychotique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antipsychotic</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antipsicótico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Trouble cognition</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude longitudinale</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Follow up study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio longitudinal</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Low dose</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>24</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Psychopathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Psychopathology</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Psicopatología</s0>
<s5>45</s5>
</fC07>
<fN21><s1>251</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 97-0412076 INIST</NO>
<ET>Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</ET>
<AU>MECO (G.); ALESSANDRI (A.); GIUSTINI (P.); BONIFATI (V.)</AU>
<AF>Department of Neurological Sciences, "La Sapienza" University/Roma/Italie (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 4; Pp. 610-612; Bibl. 9 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B03</CC>
<FD>Parkinson maladie; Psychose; Rispéridone; Antipsychotique; Trouble cognition; Chimiothérapie; Traitement; Homme; Etude longitudinale; Dose faible</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Psychopathologie</FG>
<ED>Parkinson disease; Psychosis; Risperidone; Antipsychotic; Cognitive disorder; Chemotherapy; Treatment; Human; Follow up study; Low dose</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Psychopathology</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Psicosis; Risperidona; Antipsicótico; Trastorno cognitivo; Quimioterapia; Tratamiento; Hombre; Estudio longitudinal; Dosis débil</SD>
<LO>INIST-20953.354000067729910220</LO>
<ID>97-0412076</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:97-0412076
|texte= Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
}}
| This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 | ![](Common/icons/LogoDilib.gif) |